Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial
- 1 April 2014
- journal article
- research article
- Published by Elsevier BV in The Lancet Oncology
- Vol. 15 (4), 396-405
- https://doi.org/10.1016/s1470-2045(14)70049-x
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trialThe Lancet Oncology, 2013
- Non-epithelial ovarian cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2012
- First-Line Therapy in Ovarian Cancer TrialsInternational Journal of Gynecologic Cancer, 2011
- Evaluation of New Platinum-Based Treatment Regimens in Advanced-Stage Ovarian Cancer: A Phase III Trial of the Gynecologic Cancer InterGroupJournal of Clinical Oncology, 2009
- Phase II trial of weekly paclitaxel (80 mg/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: A Gynecologic Oncology Group studyGynecologic Oncology, 2006
- A phase II trial of weekly paclitaxel and every 3 weeks of carboplatin in potentially platinum-sensitive ovarian and peritoneal carcinomaGynecologic Oncology, 2005
- Evaluation of weekly low-dose paclitaxel and carboplatin treatment for patients with platinum-sensitive relapsed ovarian cancerGynecologic Oncology, 2005
- Weekly carboplatin and paclitaxel is safe, active, and well tolerated in recurrent ovarian cancer cases of Japanese women previously treated with cisplatin-containing multidrug chemotherapyInternational Journal of Gynecologic Cancer, 2005
- Paclitaxel 175 or 225 mg per Meters Squared With Carboplatin in Advanced Ovarian Cancer: A Randomized TrialJournal of Clinical Oncology, 2004
- Phase I study with a weekly 1 h infusion of paclitaxel in heavily pretreated patients with metastatic breast and ovarian cancerEuropean Journal of Cancer, 1996